Rolapitant

(Varubi®)

Rolapitant

Drug updated on 11/10/2023

Dosage FormTablet (oral; 90 mg)
Drug ClassSubstance P/neurokinin 1 (NK1) receptor antagonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.